BRPI0516470A - uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase - Google Patents

uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase

Info

Publication number
BRPI0516470A
BRPI0516470A BRPI0516470-2A BRPI0516470A BRPI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A
Authority
BR
Brazil
Prior art keywords
type
psoriasis
prevention
treatment
interferon
Prior art date
Application number
BRPI0516470-2A
Other languages
English (en)
Inventor
Michel Gilliet
Frank O Nestle
Original Assignee
Universitot Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitot Zuerich filed Critical Universitot Zuerich
Publication of BRPI0516470A publication Critical patent/BRPI0516470A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UM AGENTE DE BLOQUEIO DO INTERFERON TIPO 1, E, MéTODO DE PREVENçãO E TRATAMENTO DA PSORìASE. A descoberta dos precursores das células dendríticas plasmacitóides (PDC) como células efetoras cruciais com alta produção dos interferons (IFNs) tipo 1 no desenvolvimento prematuro da psoríase, levou à presente invenção de acordo com a qual esse bloqueio dos IFNs tipo 1 pode ser usado para a prevenção e terapia da psoríase. A invenção diz respeito ao uso de um agente de bloqueio do interferon tipo 1, tal como um antagonista do IFN tipo 1 (por exemplo, um anticorpo anti-IFN-<244> ou antagonista do receptor do IFN tipo 1, para a preparação de um medicamento para a prevenção e tratamento da psoríase, e a um método de prevenção e tratamento da psoríase com o uso de um agente de bloqueio do interferon tipo 1.
BRPI0516470-2A 2004-10-07 2005-09-30 uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase BRPI0516470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405628 2004-10-07
PCT/CH2005/000566 WO2006037247A1 (en) 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis

Publications (1)

Publication Number Publication Date
BRPI0516470A true BRPI0516470A (pt) 2008-09-09

Family

ID=35593663

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516470-2A BRPI0516470A (pt) 2004-10-07 2005-09-30 uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase

Country Status (15)

Country Link
US (1) US20090155286A1 (pt)
EP (2) EP1796722A1 (pt)
JP (1) JP2008515819A (pt)
KR (1) KR20070083809A (pt)
CN (1) CN101056654A (pt)
AU (1) AU2005291741B2 (pt)
BR (1) BRPI0516470A (pt)
CA (1) CA2582471A1 (pt)
IL (1) IL182087A0 (pt)
MX (1) MX2007003809A (pt)
NO (1) NO20072024L (pt)
NZ (1) NZ554065A (pt)
RU (2) RU2007116988A (pt)
WO (1) WO2006037247A1 (pt)
ZA (1) ZA200702794B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100536919C (zh) 2001-01-09 2009-09-09 贝勒研究院 干扰素拮抗剂和Flt3L拮抗剂的用途
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
KR101363120B1 (ko) 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 항-인터페론 알파 모노클로날 항체 및 사용 방법
ES2549903T3 (es) 2008-05-07 2015-11-03 Argos Therapeutics, Inc. Anticuerpos humanizados contra interferón alfa humano
FR2968561B1 (fr) 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
EP2623978A1 (en) * 2012-02-03 2013-08-07 Charité - Universitätsmedizin Berlin CD8+ T-cell subsets as markers for prediction of delayed fracture healing
CN103319608B (zh) * 2013-07-01 2014-08-27 江苏众红生物工程创药研究院有限公司 猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法
AU2014365838B2 (en) 2013-12-16 2021-01-14 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
US10294301B2 (en) * 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof
US20210228687A1 (en) * 2018-06-01 2021-07-29 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
DE3211263A1 (de) * 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
WO1984003106A1 (en) * 1983-02-04 1984-08-16 Wadley Inst Of Molecular Medic Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
DE19919149A1 (de) 1999-04-27 2000-11-16 Wieser Raimund J Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
CN100536919C (zh) * 2001-01-09 2009-09-09 贝勒研究院 干扰素拮抗剂和Flt3L拮抗剂的用途
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP4966497B2 (ja) * 2002-11-15 2012-07-04 ゲンマブ エー／エス Ｃｄ２５に対するヒトモノクローナル抗体
AU2004299833B2 (en) * 2003-12-10 2009-05-07 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
KR101363120B1 (ko) * 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 항-인터페론 알파 모노클로날 항체 및 사용 방법
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use

Also Published As

Publication number Publication date
RU2010146161A (ru) 2012-05-20
NZ554065A (en) 2010-12-24
JP2008515819A (ja) 2008-05-15
CN101056654A (zh) 2007-10-17
WO2006037247A1 (en) 2006-04-13
NO20072024L (no) 2007-04-26
ZA200702794B (en) 2008-06-25
US20090155286A1 (en) 2009-06-18
RU2007116988A (ru) 2008-11-20
KR20070083809A (ko) 2007-08-24
AU2005291741A1 (en) 2006-04-13
IL182087A0 (en) 2007-07-24
EP2286835A1 (en) 2011-02-23
AU2005291741B2 (en) 2011-11-24
MX2007003809A (es) 2007-09-12
EP1796722A1 (en) 2007-06-20
CA2582471A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
BRPI0516470A (pt) uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase
Ravikirti et al. Ivermectin as a potential treatment for mild to moderate COVID-19–a double blind randomized placebo-controlled trial
Szymańska et al. Multifunctional tannic acid/silver nanoparticle-based mucoadhesive hydrogel for improved local treatment of HSV infection: In vitro and in vivo studies
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
BR112021026580A2 (pt) Conjugado anticorpo - fármaco, intermediário do mesmo, método de preparação e aplicação do mesmo
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
PT99108A (pt) Processo de preparacao de uma composicao farmaceutica a base de portadores naoaquosos de perfluorocarbonetos ou silicone fluorado
Zeichner et al. Penetration of (14C)-efinaconazole topical solution, 10%, does not appear to be influenced by nail polish
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
Zheng et al. A novel protein drug, novaferon, as the potential antiviral drug for COVID-19
Bastyr III et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure
HUP0300709A2 (hu) Pemetrexedet monotioglikollal, L-ciszteinnel vagy tioglikolsavval együtt tartalmazó gyógyászati készítmény
Sulkowski et al. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection
Tzen et al. Melas with point mutations involving tRNALeu (A3243G) and tRNAGlu (A14693g)
Shemer et al. Clinical comparison and complete cure rates of terbinafine efficacy in affected onychomycotic toenails
James Nitrous oxide: still useful in the year 2000?
BRPI0510950A (pt) membro de ligação especìfico, composição farmacêutica, método para o tratamento de um tumor em um paciente, uso de um membro de ligação, produtos, ácido nucleico, e, carboidrato de sialiltetraosila
Khan et al. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
Boudreau et al. Comparison of mefloquine, chloroquine plus pyrimethamine-sulfadoxine (Fansidar), and chloroquine as malarial prophylaxis in eastern Thailand

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.